Biotechnology News and Research

RSS

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

PsychoGenics Inc. today announced that it has entered into a strategic alliance with Evotec AG to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

Biologics Process Development Inc., a wholly-owned subsidiary of Viropro, will double the size of its existing bioprocess- and scale-up laboratory in Poway, CA.

25 May 2011

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Proteros Biostructures GmbH announced today that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K.

25 May 2011

Accelerator announces Series A financing of Oncofactor

Accelerator Corporation, a privately held, venture-capital-backed biotechnology investment and development company, announced today the Series A financing of Oncofactor Corporation. This is the twelfth company backed by Accelerator and its first investment based on internal intellectual property developed at Accelerator.

24 May 2011

LinkMed acquires NorDiag's 50% stake in Olerup International

LinkMed acquires NorDiag´s 50 percent stake in Olerup International AB, which is the holding company for Olerup GmbH. LinkMed will thereby control 75 percent of the company.

24 May 2011

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute has awarded Altor a Small Business Innovation Research Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor's efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome.

24 May 2011

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology, taking place June 3-7, 2011, at McCormick Place in Chicago.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.

23 May 2011

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood.

23 May 2011

Scientists direct embryonic, induced human stem cells to become astrocytes in lab dish

Pity the lowly astrocyte, the most common cell in the human nervous system. Long considered to be little more than putty in the brain and spinal cord, the star-shaped astrocyte has found new respect among neuroscientists who have begun to recognize its many functions in the brain, not to mention its role in a range of disorders of the central nervous system.

23 May 2011

CT scan may help determine early death in individuals with diabetes

New findings out of Wake Forest Baptist Medical Center reveal that a common test may be useful in predicting early death in individuals with diabetes.

23 May 2011

Synthon opens state-of-the-art laboratory for biotechnology

Synthon opened its state-of-the-art laboratory for biotechnology today, an important step in the company’s development into a ‘specialty pharmaceutical’ firm. Ms. Renée Bergkamp, Director-General of Enterprise and Innovation of the Ministry of Economic Affairs, Agriculture and Innovation, and Mr. Thom de Graaf, Mayor of Nijmegen, attended the official opening.

22 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

U.S. District Court grants Cephalon Temporary Restraining Order for generic AMRIX

Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc., and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX.

21 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Syngenta plans new $71 million state-of-the-art biotechnology research facility in North Carolina

Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.

21 May 2011

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL.

21 May 2011

Biotechnology News and Research

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Biogen Idec launches educational forum, 'Women in MS'

BPD expands existing bioprocess and scale-up laboratory in Poway, CA

Proteros, IP-K partner for structure-based drug discovery services in the field of infectious diseases

Accelerator announces Series A financing of Oncofactor

LinkMed acquires NorDiag's 50% stake in Olerup International

Altor receives NHLBI SBIR grant to complete ALT-836 second Phase 2 trial in ALI/ARDS

VBL to present updated VB-111 Phase 1 trial results in advanced metastatic cancer at ASCO 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Micromet's blinatumomab data to be presented at two upcoming medical meetings

Pieris' PRS-080 preclinical data in anemia presented at International BioIron Society Meeting

Scientists direct embryonic, induced human stem cells to become astrocytes in lab dish

CT scan may help determine early death in individuals with diabetes

Synthon opens state-of-the-art laboratory for biotechnology

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

U.S. District Court grants Cephalon Temporary Restraining Order for generic AMRIX

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Syngenta plans new $71 million state-of-the-art biotechnology research facility in North Carolina

Data from Seattle Genetics' brentuximab vedotin, SGN-75 programs to be presented at ASCO 2011

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News